Real-life prognosis of neurological complications of botulinum toxin: A nationwide pharmacovigilance study of adverse drug reactions reported in France between 1994 and 2020.
Abstract
[BACKGROUND] Botulinum toxin is commonly used in the treatment of neurological disorders. Although neurological complications predominate and can lead to respiratory failure or death, no observational studies have specifically described their clinical features or prognoses.
[OBJECTIVES] To characterise real-life clinical features and prognoses of botulinum toxin-related neurological complications.
[METHODS] Observational, retrospective, nationwide pharmacovigilance study of all neurological adverse drug reactions (ADRs) related to the use of botulinum toxin in France for neurological indications between 1994 and 2020. The characteristics of neurological complications were collected.
[RESULTS] In total, 141 people with systemic neurologic complications (ie, distant from the injection site) and 50 with local complications were included. Median (IQR) age was 53 (36; 66) years, and 107 (56 %) were women. The estimated incidence range (min-max) was 25 - 413 neurologic ADRs per 100 000 injection sessions for neurological indications. Except for 3 miscellaneous cases, all presented symptoms within the clinical spectrum of botulism, either as an isolated symptom (41 %) or as multiple symptoms (59 %), with a time to onset of 12 (7; 15) days after injection and a duration of 54 (28; 90) days. A total of 87 % of cases recovered spontaneously or were recovering on the date of the notification. Drug types were not different between cases with systemic or local ADRs, although the doses were higher in cases with systemic ADRs (P < 0.001). Serious cases were more frequent for systemic ADRs (67 % versus 34 %; P < 0.001). Three complications resulted in death, all after treatment for cervical dystonia or sialorrhea.
[CONCLUSION] In this pharmacovigilance study, the outcomes of botulism spectrum symptoms occurring after a botulinum toxin injection for a neurological indication were mostly favourable, although symptoms were often initially serious.
[OBJECTIVES] To characterise real-life clinical features and prognoses of botulinum toxin-related neurological complications.
[METHODS] Observational, retrospective, nationwide pharmacovigilance study of all neurological adverse drug reactions (ADRs) related to the use of botulinum toxin in France for neurological indications between 1994 and 2020. The characteristics of neurological complications were collected.
[RESULTS] In total, 141 people with systemic neurologic complications (ie, distant from the injection site) and 50 with local complications were included. Median (IQR) age was 53 (36; 66) years, and 107 (56 %) were women. The estimated incidence range (min-max) was 25 - 413 neurologic ADRs per 100 000 injection sessions for neurological indications. Except for 3 miscellaneous cases, all presented symptoms within the clinical spectrum of botulism, either as an isolated symptom (41 %) or as multiple symptoms (59 %), with a time to onset of 12 (7; 15) days after injection and a duration of 54 (28; 90) days. A total of 87 % of cases recovered spontaneously or were recovering on the date of the notification. Drug types were not different between cases with systemic or local ADRs, although the doses were higher in cases with systemic ADRs (P < 0.001). Serious cases were more frequent for systemic ADRs (67 % versus 34 %; P < 0.001). Three complications resulted in death, all after treatment for cervical dystonia or sialorrhea.
[CONCLUSION] In this pharmacovigilance study, the outcomes of botulism spectrum symptoms occurring after a botulinum toxin injection for a neurological indication were mostly favourable, although symptoms were often initially serious.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 시술 | botulinum toxin
|
보툴리눔독소 주사 | dict | 5 | |
| 해부 | cervical
|
scispacy | 1 | ||
| 약물 | [BACKGROUND] Botulinum toxin
|
scispacy | 1 | ||
| 약물 | [OBJECTIVES]
|
scispacy | 1 | ||
| 약물 | [RESULTS]
|
scispacy | 1 | ||
| 질환 | adverse drug reactions
|
C0041755
Adverse reaction to drug
|
scispacy | 1 | |
| 질환 | neurological disorders
|
C0027765
nervous system disorder
|
scispacy | 1 | |
| 질환 | neurological complications
|
C0235029
neurological complication
|
scispacy | 1 | |
| 질환 | respiratory failure
|
C1145670
Respiratory Failure
|
scispacy | 1 | |
| 질환 | death
|
C0011065
Cessation of life
|
scispacy | 1 | |
| 질환 | neurological adverse drug reactions
|
scispacy | 1 | ||
| 질환 | systemic neurologic complications
|
scispacy | 1 | ||
| 질환 | botulism
|
C0006057
Botulism
|
scispacy | 1 | |
| 질환 | dystonia
|
C0013421
Dystonia
|
scispacy | 1 | |
| 질환 | sialorrhea
|
C0037036
Sialorrhea
|
scispacy | 1 | |
| 질환 | botulism spectrum symptoms
|
scispacy | 1 | ||
| 기타 | botulinum toxin:
|
scispacy | 1 | ||
| 기타 | botulinum toxin-related
|
scispacy | 1 | ||
| 기타 | people
|
scispacy | 1 | ||
| 기타 | women
|
scispacy | 1 |
MeSH Terms
Humans; Pharmacovigilance; Female; France; Male; Middle Aged; Retrospective Studies; Adult; Aged; Nervous System Diseases; Botulinum Toxins; Prognosis; Neuromuscular Agents; Drug-Related Side Effects and Adverse Reactions; Botulism
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- Local therapeutic strategies for neurocutaneous dysesthesia: from capsaicin to cannabinoids.
- Comparative efficacy of intralesional therapies for keloid scars: a network meta-analysis.
- Adverse neurological events following botulinum toxin type A: A case series of post-injection seizures and paralysis.
- Decreased utilization of component separation techniques over time in complex abdominal wall reconstruction following introduction of preoperative botulinum toxin A.
- Current Perspectives on Pectoralis Minor Syndrome: A Narrative Review.